Skip to main content

Hepion Pharmaceuticals, Inc.

corporate_fare Company Profile

Hepion Pharmaceuticals, Inc.

HEPA·OTC·Life Sciences·CIK 0001583771

Hepion Pharmaceuticals, Inc. is a medical diagnostic company headquartered in Morristown, New Jersey. The company previously focused on developing drug therapy for chronic liver diseases, with its lead molecule being rencofilstat (formerly CRV431), a cyclophilin inhibitor. Rencofilstat is a compound that binds and inhibits cyclophilins, a class of isomerase enzymes that regulate protein folding. Cyclophilins A, B, and D are the best-characterized isoforms in humans, and their inhibition has shown therapeutic effects in various experimental models, including liver disease models. On April 19, 2024, the company announced the wind-down of its ASCEND-NASH clinical trial due to insufficient funding to complete the study as designed. All clinical trial activities were completed, and the trial was closed in August 2024. On May 9, 2025, Hepion Pharmaceuticals entered into a License Agreement with New Day Diagnostics LLC to in-license certain diagnostic tests. These tests cover celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex, and H. pylori tests have CE marks, making them eligible for sale in the European Union and certain other markets that accept the CE mark, excluding the United States at present. Under the License Agreement, Hepion Pharmaceuticals paid New Day $525,000 in cash and $270,629 in shares of its common stock, and agreed to pay up to $17.15 million upon achieving specific regulatory, sales, and reimbursement milestones.

Hepion Pharmaceuticals, Inc. (OTC:HEPA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 9 items for HEPA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 7/10. Across its 9 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for HEPA spans 8-K, 10-K.

Recent high-impact activity:

  • FDA Backs GV104 Prophylaxis Path After Simulation Prevents All Fentanyl Cardiac Arrests
  • FDA Backs 505(b)(2) Path for GV104 in Gambling Disorder, IND Targeted for 2027
  • Hepion Closes Gravitas Acquisition, Gains FDA-Endorsed Opioid Countermeasure
  • Hepion Pharmaceuticals Finalizes CEO Separation Agreement, Discloses $255K Payout Amidst Going Concern Warning
  • Hepion Pharmaceuticals CEO Resigns Amidst Financial Distress; Interim CEO and New Directors Appointed

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 15 shares in HEPA as of the October 30, 2026 settlement, a 99.6% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 19.1% of HEPA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)15 shares as of October 30, 2026
Change vs prior period▼ 99.6%
Days to cover1.00 at avg daily volume of 57,766
Daily short volume (FINRA facilities)19.1% of 50,109 shares on November 20, 2026
5-day average short volume32.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with H →
$0.1187 +17.52% today
52-week range · as of 2026-04-14 $0.033 – $0.7464
Market cap
$14.85M
Volume
50.1K (1.4× avg)
3-mo avg 34.6K
Live data · 2026-11-21 11:55 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HEPA - Latest Insights

HEPA
Oct 26, 2026, 8:01 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.140
Real-time Price: $0.1187 info
Change: -$0.0213 (-15%) info
Market Cap: $14.846M info
HEPA
Oct 19, 2026, 8:01 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.1036
Real-time Price: $0.1187 info
Change: +$0.0151 (+15%) info
Market Cap: $14.846M info
HEPA
Oct 14, 2026, 8:01 AM EDT
Source: ACCESS Newswire
Importance Score:
7
Price at Filing: $0.061
Real-time Price: $0.1187 info
Change: +$0.0577 (+95%) info
Market Cap: $14.846M info
HEPA
Apr 14, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.048
Real-time Price: $0.1187 info
Change: +$0.0707 (+147%) info
Market Cap: $14.846M info
HEPA
Mar 18, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.0433
Real-time Price: $0.1187 info
Change: +$0.0754 (+174%) info
Market Cap: $14.846M info
HEPA
Mar 12, 2026, 6:15 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.045
Real-time Price: $0.1187 info
Change: +$0.0737 (+164%) info
Market Cap: $14.846M info
HEPA
Mar 11, 2026, 9:43 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.045
Real-time Price: $0.1187 info
Change: +$0.0737 (+164%) info
Market Cap: $14.846M info
HEPA
Mar 03, 2026, 8:11 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0396
Real-time Price: $0.1187 info
Change: +$0.0791 (+200%) info
Market Cap: $14.846M info
HEPA
Jan 15, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.060
Real-time Price: $0.1187 info
Change: +$0.0587 (+98%) info
Market Cap: $14.846M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets